Advisory Panelists' Experience Carries Weight In Acthar Debate
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Peripheral and Central Nervous System Drugs Advisory Committee members cite their own use of the drug in voting that Acthar Gel is effective at treating infantile spasms.
You may also be interested in...
Acthar PDUFA Date Delayed As FDA Reviews Post-Approval Commitments
Advisory committee had recommended trials on side effects, sustainability, dosing and safety for the infantile spasms indication, which the firm was concerned would be unethical.
Acthar PDUFA Date Delayed As FDA Reviews Post-Approval Commitments
Advisory committee had recommended trials on side effects, sustainability, dosing and safety for the infantile spasms indication, which the firm was concerned would be unethical.
New Challenge For Acthar Is Labeling; Practitioners Disagree On Dosing
Having gathered an advisory committee's endorsement that Questcor Pharmaceutical's Acthar (corticotropin) is effective for treating infantile spasms - a common off-label use - the remaining challenge for FDA is determining how the drug should be used in that indication